Alicia Morgans, MD, MPH, discusses how the ARANOTE trial not only demonstrated clinical efficacy for the combination of ADT and darolutamide, but also highlighted key quality-of-life benefits that ...

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...